Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level
Menés respectivement sur 135 et 86 patients atteints d'un mélanome de stade avancé, ces deux essais évaluent le lambrolizumab et le nivolumab, deux anticorps anti PD-1, avec ou sans traitement par ipilimumab, un anticorps anti CTLA-4
Wolchok et al. and Hamid et al. report in the Journal the results of phase 1 clinical trials showing that the combination of PD-1 and CTLA-4 antibody blockers leads to improved treatment outcomes in patients with melanoma, without an escalation of toxic effects. The results of these trials are striking and complementary...
New England Journal of Medicine , éditorial en libre accès, 2012